June 2nd 2023
Adam D. Cohen, MD, discusses unmet needs and areas for future investigation within the relapsed/refractory multiple myeloma treatment landscape.
March 15th 2023
Adam D. Cohen, MD, discusses the current landscape of treatment options in multiple myeloma, and elaborates on attempts to utilize these options in earlier lines of therapy.
August 28th 2022
Adam D. Cohen, MD, discusses the efficacy of ciltacabtagene autoleucel in patients with lenalidomide-refractory multiple myeloma.
October 28th 2021
Adam D. Cohen, MD, discusses the safety profile of ciltacabtagene autoleucel in patients with multiple myeloma, based on data from the phase 2 CARTITUDE-2 study.
September 27th 2021
Adam D. Cohen, MD, discusses outcomes with ciltacabtagene autoleucel, as demonstrated in the phase 2 CARTITUDE-2 study in patients with multiple myeloma.
September 21st 2021
Adam D. Cohen, MD, discusses mitigation strategies that can be used for patients with relapsed/refractory multiple myeloma who are receiving the CAR T-cell therapy ciltacabtagene autoleucel.
October 31st 2019
Adam D. Cohen, MD, discusses the ongoing phase II DREAMM-2 study in multiple myeloma.